Shuttle Pharma enters $291K sponsored research agreement with UCSF for PSMA-B theranostic development

Shuttle Pharmaceuticals Holdings, Inc.

Sponsored research agreement with UCSF, $291,607 cost, 1-year term, for preclinical PSMA-B ligand development.
UCSF will develop radiosynthetic methods for [18F]FPA-ACUPA probe and test binding in prostate cancer cell lines and mouse models.
Shuttle holds exclusive license to PSMA-B IP and has filed a patent application with USPTO.
PSMA-B ligand is a theranostic candidate for prostate cancer diagnosis and therapy, with market opportunities cited.
Pluvicto market predicted at $2B; PSMA PET imaging market expected to reach $2.0B by 2030.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.